Why Elevated PTH Levels Occur During Osteoporosis Treatment with Prolia and Reclast

In this video, Dr. Tahir, a Rheumatologist, and Obesity Medicine specialist explain why elevated parathyroid hormone (PTH) levels can occur in patients receiving osteoporosis treatment with anti-resorptive medications like Prolia (denosumab) and Reclast (zoledronic acid), even when vitamin D, calcium, and comprehensive metabolic panel (CMP) results are expected. Dr. Tahir dives into the mechanisms behind this phenomenon, including the suppression of bone turnover, calcium-sensing receptor sensitivity, feedback mechanisms, and more.
If you’re interested in learning more about bone health and treatments for osteoporosis, be sure to like this video and subscribe to the channel for regular updates on staying youthful and healthy.
Keywords:
Elevated PTH during osteoporosis treatment
Parathyroid hormone and osteoporosis
Prolia PTH levels
Reclast PTH levels
Anti-resorptive medications and PTH
Osteoporosis treatment side effects
Bone health medications
Calcium balance in osteoporosis
Secondary hyperparathyroidism
Denosumab vs. Zoledronic acid